<DOC>
	<DOCNO>NCT00637767</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , melphalan , work different way stop growth cancer cell , either kill cell stop dividing . Radiolabeled monoclonal antibody find cancer cell carry cancer-killing substance without harm normal cell . A stem cell transplant use stem cell patient may able replace blood-forming cell destroy chemotherapy radiolabeled monoclonal antibody . PURPOSE : This randomized phase II trial study well high-dose melphalan work give without radiolabeled monoclonal antibody treat patient multiple myeloma undergo autologous stem cell transplant .</brief_summary>
	<brief_title>High-Dose Melphalan With Without Radiolabeled Monoclonal Antibody Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine efficacy high-dose melphalan ( 200mg/m² ) combination target radiotherapy deliver yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 , term disease response ( complete remission rate change serum free light chain level treatment yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 ) , patient undergo autologous hematopoietic stem cell transplantation multiple myeloma . Secondary - To determine toxicity profile yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 context autologous hematopoietic stem cell transplantation . - To determine effect target radiotherapy parameter disease response , term proportion patient partial remission , stable disease , progressive disease , remission duration ( time disease progression ) , overall survival . - To determine effect target radiotherapy engraftment use combination high-dose melphalan patient undergo autologous hematopoietic stem cell transplantation multiple myeloma . - To investigate pharmacokinetic behavior indium In 111 anti-CD66 monoclonal antibody BW250/183 ( use dosimetry ) . - To continue develop dosimetry model base single-photon emission compute tomography ( SPECT ) whole body gamma camera image follow administration radiolabeled anti-CD66 monoclonal antibody ( subset patient Southampton site ) . - To assess proportion patient form human anti-murine antibody ( HAMA ) treatment target radiotherapy context autologous hematopoietic stem cell transplantation . OUTLINE : This multicenter study . Patients stratify accord disease risk group ( low risk [ beta-2 microglobulin C-reactive protein &lt; 6 either beta-2 microglobulin C-reactive protein ≥ 6 ] v high risk [ beta-2 microglobulin C-reactive protein ≥ 6 ] ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive dosimetry dose indium In 111 anti-CD66 monoclonal antibody BW250/183 IV day 1 undergo gamma camera image serial blood sample day 1-5 . Patients receive therapeutic dose yttrium Y 90 anti-CD66 monoclonal antibody BW250/183 IV day 9 16 high-dose melphalan IV day 28 . Patients undergo autologous hematopoietic stem cell transplantation ( HSCT ) day 30 . - Arm II : Patients receive high-dose melphalan IV day 1 . Patients undergo autologous HSCT day 3 . Patients arm I undergo blood sample collection periodically pharmacokinetic pharmacodynamic study analysis human anti-murine antibody ( HAMA ) status . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven multiple myeloma ( MM ) Scheduled undergo autologous hematopoietic stem cell transplantation ( HSCT ) consolidation treatment MM Must sufficient CD34positive stem cell ( ≥ 4 x 10^6 cell per kg body weight ) cryostorage two autologous HSCTs In partial remission ( PR ) prior chemotherapy prim therapy stem cell mobilization Patients complete remission ( CR ) prior chemotherapy eligible Bone marrow cellularity ≥ 20 % PATIENT CHARACTERISTICS : WHO performance status 01 Life expectancy ≥ 24 week Hemoglobin ≥ 9.0 g/dL Neutrophils ≥ 1,500/mm³ Platelets ≥ 50,000/mm³ Serum bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT and/or AST ≤ 2.5 time ULN Creatinine clearance ≥ 50 mL/min Not pregnant nursing Negative pregnancy test Fertile female patient must use effective contraception 4 week prior , , 6 month completion study treatment Fertile male patient must use effective contraception 6 month completion study treatment Able cooperate study treatment follow Human antimouse antibody ( HAMA ) negative No active uncontrolled infection No highrisk nonmalignant systemic disease No condition , investigator 's opinion , would make patient unsuitable candidate study No known HIV hepatitis B C seropositivity No history allergy , include allergy rodent rodent proteins No history eczema asthma No history New York Heart Association ( NYHA ) class III IV cardiac disease No congestive heart failure PRIOR CONCURRENT THERAPY : Recovered prior therapy Alopecia certain grade 1 toxicity allow More 4 week since prior radiotherapy ( except localize pain control ) , endocrine therapy , immunotherapy More 4 week since prior concurrent chemotherapy underlie hematological condition , except follow : Cyclophosphamide prim stem cell harvest Thalidomide More 3 week since prior major thoracic and/or abdominal surgery recover No prior highdose therapy autologous HSCT Concurrent radiotherapy allow control bone pain The irradiated lesion use response evaluation No concurrent anticancer therapy investigational drug transplantation conditioning</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2009</verification_date>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
</DOC>